propranolol has been researched along with Multiple Hemangioblastomas in 4 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "HeLa 9X (HRE) hypoxia responsive element cell line and primary hemangioblastoma-derived cells were subjected to propranolol treatment and cell viability and apoptosis were evaluated." | 7.81 | Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients. ( Albiñana, V; Botella, LM; de Campos, JM; Mota-Pérez, M; Perona-Moratalla, AB; Segura, T; Serrano-Heras, G; Villar Gómez de Las Heras, K, 2015) |
| "Propranolol was initiated with a progressive increase up to a final dose of 120 mg daily." | 5.46 | Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease. ( Albiñana, V; Botella, LM; Escribano, RMJ; Padial, LR; Recio-Poveda, L; Soler, I; Villar Gómez de Las Heras, K, 2017) |
| "HeLa 9X (HRE) hypoxia responsive element cell line and primary hemangioblastoma-derived cells were subjected to propranolol treatment and cell viability and apoptosis were evaluated." | 3.81 | Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients. ( Albiñana, V; Botella, LM; de Campos, JM; Mota-Pérez, M; Perona-Moratalla, AB; Segura, T; Serrano-Heras, G; Villar Gómez de Las Heras, K, 2015) |
| "Propranolol was initiated with a progressive increase up to a final dose of 120 mg daily." | 1.46 | Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease. ( Albiñana, V; Botella, LM; Escribano, RMJ; Padial, LR; Recio-Poveda, L; Soler, I; Villar Gómez de Las Heras, K, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albiñana, V | 3 |
| Recio-Poveda, L | 2 |
| González-Peramato, P | 1 |
| Martinez-Piñeiro, L | 1 |
| Botella, LM | 3 |
| Cuesta, AM | 1 |
| Escribano, RMJ | 1 |
| Soler, I | 1 |
| Padial, LR | 1 |
| Villar Gómez de Las Heras, K | 2 |
| Hernández-Martínez, P | 1 |
| Gallego-Pinazo, R | 1 |
| Dolz-Marco, R | 1 |
| Arevalo, JF | 1 |
| Díaz-Llopis, M | 1 |
| Cisneros Lanuza, A | 1 |
| Serrano-Heras, G | 1 |
| Segura, T | 1 |
| Perona-Moratalla, AB | 1 |
| Mota-Pérez, M | 1 |
| de Campos, JM | 1 |
4 other studies available for propranolol and Multiple Hemangioblastomas
| Article | Year |
|---|---|
Blockade of β2-Adrenergic Receptor Reduces Inflammation and Oxidative Stress in Clear Cell Renal Cell Carcinoma.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Hemangiobl | 2022 |
Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease.
Topics: Adolescent; Adult; Biomarkers; Female; Hemangioblastoma; Humans; Male; MicroRNAs; Middle Aged; Propr | 2017 |
Oral propranolol and intravitreal ranibizumab for refractory serous macular detachment secondary to retinal capillary hemangioblastoma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Angiogenesis Inhibitors; Combined Modality | 2015 |
Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Apoptosis; Cell Survival; Cerebellar Neoplasms; Dose | 2015 |